Login to Your Account

Clinic Roundup

Thursday, December 22, 2011

• Celldex Therapeutics Inc., of Needham, Mass., completed accrual for its Phase IIb (EMERGE) trial of CDX-011 (glembatamumab vedotin) for metastatic breast cancer. The drug targets glycoprotein NMB (GPNMB). The randomized, controlled trial enrolled heavily pre-treated breast cancer patients unlikely to benefit from any approved therapies and whose tumors express GPNMB. Endpoints include response rate and progression-free survival. The trial is being carried out at 20 sites within the U.S.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription